You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Patients

How do you treat your severe asthma patients who remain uncontrolled despite high-dose inhaled corticosteroid (ICS) and controller medications, or who are only controlled with the addition of maintenance oral corticosteroids (OCS)? Some of these patients may have severe refractory eosinophilic asthma. The case profiles below can help you identify these patients potentially eligible for Nucala (mepolizumab) treatment.
 

Discover Nucala

Meet Violet

Age:

50 years

Presentation:

She uses a high-dose ICS/LABA, but still experienced four exacerbations last year. Since then she has been worried about her next exacerbation.

Discover Nucala

Meet Andy

Age:

39 years

Presentation:

He’s feeling very low about his uncontrolled asthma and is concerned about his recent weight gain due to long-term OCS use.
 

Discover Nucala

Could Nucala help your severe refractory eosinophilic asthma patients?

Prescribing information

Studies

See for yourself how Nucala showed long term safety and efficacy in the COLUMBA trial, 1and learn more about how your patients on OCS could reduce their daily dose while maintaining asthma control.
 

Your resources

Click below to access a range of resources to support your use of Nucala in patients with severe refractory eosinophilic asthma patients.

Abbreviations

OCS, oral corticosteroids; ICS, high-dose inhaled corticosteroid; LABA, Long-acting beta-adrenoceptor agonist

Indications:

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older3

Nucala is presented as a vial containing 100mg powder for solution for injection.

The dose for adults and adolescents aged 12 and older is 100mg subcutaneously every four weeks.

The dose for children aged 6-11 years is 40mg subcutaneously every four weeks.

References:

  1. Khatri et al J Allergy Clin Immunol. 2018 doi; 10.1016/j.jaci.2018.09.033
  2. Bel et al N Engl J Med 2014; DOI: 10.1056/NEJMoa1403291
  3. Nucala SmPC, 2018.